Our progress
![image](/media/woiiusvh/mereo-news.jpg?rxy=0.5078167750660559,0.4930508274395921&width=830&height=467&v=1da422ba618efd0)
Mereo BioPharma to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
London, April 3, 2024 - Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that Dr. Denise Scots-Knight, Chief Executive Officer, will participate in a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024, at 10:15am ET / 03:15pm BST.
![image](/media/woiiusvh/mereo-news.jpg?rxy=0.5078167750660559,0.4930508274395921&width=392&height=250&v=1da422ba618efd0)
Mereo BioPharma Reports Full Year 2023 Financial Results and Provides Corporate Update
27 March 2024
London, March 27, 2024 - Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its financial results for the full year ended December 31, 2023, and provided an update on recent corporate highlights.
![image](/media/woiiusvh/mereo-news.jpg?rxy=0.5078167750660559,0.4930508274395921&width=830&height=467&v=1da422ba618efd0)
Mereo BioPharma to Participate in Fireside Chat at the Leerink Partners Global Biopharma Conference
London, March 5, 2024 - Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that Dr. Denise Scots-Knight, Chief Executive Officer, will participate in a Fireside Chat at the Leerink Partners Global Biopharma Conference on Tuesday, March 12, 2024 at 11:20am ET / 03:20pm GMT.
![image](/media/k4lby4un/_mg_5205.jpg?width=392&height=250&v=1d9e180e01cfd40)
Mereo BioPharma Provides Update on Pipeline Progress and Corporate Developments
08 January 2024
LONDON, January 08, 2024 – Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today provided an update on its pipeline programs as well as an update on recent corporate developments.